cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Foghorn Therapeutics Inc
4 own
3 watching
Current Price
$4.06
$-0.32
(-7.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
434.33M
52-Week High
52-Week High
10.25
52-Week Low
52-Week Low
2.70000
Average Volume
Average Volume
0.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization434.33M
icon52-Week High10.25
icon52-Week Low2.70000
iconAverage Volume0.12M
iconDividend Yield--
iconP/E Ratio--
What does the Foghorn Therapeutics Inc do?
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.
Read More
How much money does Foghorn Therapeutics Inc make?
News & Events about Foghorn Therapeutics Inc.
PR Newswire
1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX PR Newswire NEW YORK, May 2, 2023 NEW YORK, May 2, 2023...
PR Newswire
1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX PR Newswire NEW YORK, April 26, 2023 NEW YORK, April 26, 2023...
Globe Newswire
1 year ago
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at Cowens 43rd Annual...
Globe Newswire
2years ago
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a selective degrader of BRD9, in synovial sarcoma continues to ...
Ticker Report
2years ago
Research analysts at BMO Capital Markets began coverage on shares of Foghorn Therapeutics (NASDAQ:FHTX Get Rating) in a research report issued on Thursday, The Fly reports. The brokerage set an outperform rating and a $20.00 price target on the stock. BMO Capital Markets&#8217...
Frequently Asked Questions
Frequently Asked Questions
What is Foghorn Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Foghorn Therapeutics Inc shares?
plus_minus_icon
How can I buy Foghorn Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Foghorn Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Foghorn Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Foghorn Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Foghorn Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Foghorn Therapeutics Inc?
plus_minus_icon
What percentage is Foghorn Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Foghorn Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.06
$-0.32
(-7.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00